150
Participants
Start Date
May 31, 2006
Primary Completion Date
September 30, 2008
Study Completion Date
September 30, 2008
Tovaxin Autologous T cell vaccine
subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Placebo
subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
Winthrop University Hospital - Clinical Trials Unit, Mineola
Upstate Clinical Research, LLC, Albany
University of Pennsylvania, Philadelphia
Capitol Neurology, Charleston
Raleigh Neurology Associates, Raleigh
Neurology Consultants of the Carolinas, PA, Charlotte
Shepherd Center, Atlanta
Medical College of Georgia - Department of Neurology, Augusta
Neurological Associates, Pompano Beach
Bradenton Neurology, Bradenton
Lovelace Scientific Resources, Sarasota
North Central Neurology Associates, PC, Cullman
University of Louisville Hospital, Louisville
Associates in Neurology, Lexington
Neurological Research Institute, Columbus
Neurology & Neuroscience Associates, Inc., Akron
Neurology Specialists, Inc, Dayton
Allied Physicians Inc, Fort Wayne
St Mary's of Michigan - Field Neuroscience Institute, Saginaw
Consultants in Neurology, Ltd., Northbrook
MidAmerica Neuroscience Institute, Lenexa
Research Nurse Specialists, Lafayette
The Maxine Mesinger MS Clinic/Baylor College of Medicine, Houston
Integra Clinical Research, LLC, San Antonio
Central Texas Neurology, Round Rock
Patricia A Fodor, PC, Colorado Springs
Xenoscience - 21st Century Neurology, Phoenix
HOPE Research Institute, Phoenix
Alta Bates Summit Medical Center - East Bay Physicians Medical Group, Berkeley
Providence St. Vincent Medical Center - Northwest MS Center, Portland
MS Center at Evergreen, Kirkland
Ayres & Associates Clinical Trials, Lebanon
University Hospital and Medical Center Stony Brook New York, Stony Brook
Lead Sponsor
Opexa Therapeutics, Inc.
INDUSTRY